Head-To-Head Analysis: Coeptis Therapeutics (COEP) vs. Its Rivals

Coeptis Therapeutics (NASDAQ:COEP) is one of 289 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Coeptis Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Valuation and Earnings

This table compares Coeptis Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.39
Coeptis Therapeutics Competitors	$546.11 million	-$37.14 million	5.79

Coeptis Therapeutics’ rivals have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Coeptis Therapeutics has a beta of -0.89, suggesting that its share price is 189% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ rivals have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Coeptis Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	1	0	3.00
Coeptis Therapeutics Competitors	1431	4565	11942	206	2.60

Coeptis Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 817.43%. As a group, “Biological products, except diagnostic” companies have a potential upside of 123.72%. Given Coeptis Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Coeptis Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Coeptis Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-4,499.00%	-224.48%	-45.27%

Summary

Coeptis Therapeutics rivals beat Coeptis Therapeutics on 7 of the 13 factors compared.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.